Prediction of pre‐eclampsia and adverse pregnancy outcomes with biomarkers has been proposed. AMH is an ovary‐specific growth factor, used to predict ovarian reserve, which changes with age similar to the change in age‐related fertility.

The aim of the study was to determine whether AMH tested in the first trimester of pregnancy was associated with pregnancy hypertension or adverse pregnancy outcomes.

Materials and Methods
Retrospective cohort study of women who delivered singleton fetuses ≥20 weeks’ gestation at Royal Hospital for Women, Sydney, Australia (n = 331). AMH was tested in 2011 via Beckman‐Coulter Gen II ELISA method on frozen serum collected at the time of first trimester aneuploidy screening (10–13 + 6 weeks’ gestation). Outcome data were obtained from the hospital database (ObstetriX). Main outcome measures were pregnancy hypertension (pre‐eclampsia and gestational hypertension) and composite adverse pregnancy outcome.

The median AMH level was 9.7pmol/L (interquartile range (IQR) 3.9–17.3). There was a trend towards women with pregnancy hypertension having lower AMH levels than women without pregnancy hypertension (median 5.1pmol/L, IQR 1.5–13.2 vs 9.4 IQR 3.9–17.3; P = 0.06). After adjusting for BMI ≥25, parity ≥1 and age ≥35, women with an AMH less than the 10th centile had a 3.3‐fold increased risk of pregnancy hypertension (OR 3.3, 95% CI 1.2–8.7, P = 0.01). There were no other associations between low AMH concentration and adverse maternal or neonatal outcomes.

Women with a very low AMH (1.5 pmol/L) in early pregnancy may have an increased risk of pregnancy hypertension. No other adverse pregnancy outcomes were identified.